Cell Death and Disease (Nov 2022)

Downregulating PDPK1 and taking phillyrin as PDPK1-targeting drug protect hepatocytes from alcoholic steatohepatitis by promoting autophagy

  • Yuan Zhang,
  • Yuhao Ding,
  • Huizi Zhao,
  • Zhonghao Wang,
  • Fanle Zeng,
  • Zhenzhen Qian,
  • Jun Li,
  • Taotao Ma,
  • Cheng Huang

DOI
https://doi.org/10.1038/s41419-022-05422-3
Journal volume & issue
Vol. 13, no. 11
pp. 1 – 14

Abstract

Read online

Abstract The health risk stemming from drinking alcohol is serious, sometimes even life-threatening. Alcoholic steatohepatitis (ASH) is a critical stage leading to cirrhosis and end-stage liver disease. However, its pathogenesis is still far from clearly understood, and a treatment that is widely recognised as effective has not been discovered. Interestingly, PDPK1,3-phosphoinositide-dependent protein kinase 1, also known as PDK1, was observed to be obviously increased in the ASH model by our researchers. We also investigated the protective role of autophagy in ASH. Here, we studied the function of PDPK1 and found an efficient treatment to alleviate symptoms by targeting PDPK1 in ASH. In our study, PDPK1 affected hepatocyte self-healing by inhibiting autophagy. Both inhibiting PDPK1 and the phosphorylation of PDPK1 (ser241) could protect hepatocytes from suffering heavy alcoholic hepatitis.